{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:13:01Z","timestamp":1774627981300,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100021828","name":"German Academic Exchange Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004869","name":"Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13318-026-00986-3","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:21:44Z","timestamp":1772540504000},"page":"205-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Pharmacogenetics on Tramadol Pharmacokinetics: A Population Pharmacokinetic Model"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-2626","authenticated-orcid":false,"given":"Paula","family":"Soria-Chacartegui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7617-183X","authenticated-orcid":false,"given":"Gudrun","family":"W\u00fcrthwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-4320","authenticated-orcid":false,"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-191X","authenticated-orcid":false,"given":"Susana","family":"Almenara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-6600","authenticated-orcid":false,"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-6423","authenticated-orcid":false,"given":"Georg","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"986_CR1","unstructured":"Dhesi M, Maldonado KA, Patel P, Maani CV. Tramadol. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"986_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","volume":"43","author":"S Grond","year":"2004","unstructured":"Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879\u2013923. https:\/\/doi.org\/10.2165\/00003088-200443130-00004.","journal-title":"Clin Pharmacokinet"},{"key":"986_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.phrs.2006.11.003","volume":"55","author":"E Garc\u00eda-Quetglas","year":"2007","unstructured":"Garc\u00eda-Quetglas E, Azanza J, Sadaba B, Munoz M, Gil I, Campanero M. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res. 2007;55:122\u201330. https:\/\/doi.org\/10.1016\/j.phrs.2006.11.003.","journal-title":"Pharmacol Res"},{"key":"986_CR4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/FPC.0000000000000057","volume":"24","author":"L Gong","year":"2014","unstructured":"Gong L, Stamer UM, Tzvetkov MV, Altman RB, Klein TE. Tramadol pathway. Pharmacogenet Genom. 2014;24:374\u201380. https:\/\/doi.org\/10.1097\/FPC.0000000000000057.","journal-title":"Pharmacogenet Genom"},{"key":"986_CR5","volume-title":"Medical genetics summaries","author":"L Dean","year":"2012","unstructured":"Dean L. Fluorouracil therapy and DPYD genotype. In: Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, et\u00a0al., editors. Medical genetics summaries. Bethesda: National Center for Biotechnology Information (US); 2012."},{"key":"986_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13698","volume":"17","author":"A Casaj\u00fas","year":"2023","unstructured":"Casaj\u00fas A, Zubiaur P, Alday E, Soria-Chacartegui P, Saiz-Rodriguez M, Gutierrez L, et\u00a0al. Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain. Clin Transl Sci. 2023;17:e13698. https:\/\/doi.org\/10.1111\/cts.13698.","journal-title":"Clin Transl Sci"},{"key":"986_CR7","unstructured":"Spanish Drug Agency FICHA TECNICA TRAMADOL ASTA MEDICA 100 MG\/ML GOTAS ORALES EN SOLUCI\u00d3N EFG."},{"key":"986_CR8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/j.1552-4604.1998.tb05794.x","volume":"38","author":"PA Moore","year":"1998","unstructured":"Moore PA, Crout RJ, Jackson DL, Schneider LG, Graves RW, Bakos L. Analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction. J Clin Pharmacol. 1998;38:554\u201360. https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb05794.x.","journal-title":"J Clin Pharmacol"},{"key":"986_CR9","unstructured":"Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"986_CR10","volume-title":"Medical genetics summaries","author":"L Dean","year":"2012","unstructured":"Dean L, Kane M. Tramadol therapy and CYP2D6 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. Bethesda: National Center for Biotechnology Information (US); 2012."},{"key":"986_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/PGPM.S239222","volume":"13","author":"GS Lopes","year":"2020","unstructured":"Lopes GS, Bielinski SJ, Moyer AM, Black JLIII, Jacobson DJ, Jiang R, et\u00a0al. Sex differences in associations between CYP2D6 phenotypes and response to opioid analgesics. PGPM. 2020;13:71\u20139. https:\/\/doi.org\/10.2147\/PGPM.S239222.","journal-title":"PGPM"},{"key":"986_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2149","author":"KR Crews","year":"2021","unstructured":"Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et\u00a0al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021. https:\/\/doi.org\/10.1002\/cpt.2149.","journal-title":"Clin Pharmacol Ther"},{"key":"986_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Introduction to pharmacokinetic modeling methods. CPT Pharmacometr Syst Pharmacol. 2013;2:e38. https:\/\/doi.org\/10.1038\/psp.2013.14.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"986_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40266-019-00681-w","volume":"36","author":"SS Robertson","year":"2019","unstructured":"Robertson SS, Mouksassi MS, Varin F. Population pharmacokinetic\/pharmacodynamic modeling of O-desmethyltramadol in young and elderly healthy volunteers. Drugs Aging. 2019;36:747\u201358. https:\/\/doi.org\/10.1007\/s40266-019-00681-w.","journal-title":"Drugs Aging"},{"key":"986_CR15","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1007\/s11095-006-9049-7","volume":"23","author":"MJ Garrido","year":"2006","unstructured":"Garrido MJ, Habre W, Rombout F, Troc\u00f3niz IF. Population pharmacokinetic\/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res. 2006;23:2014\u201323. https:\/\/doi.org\/10.1007\/s11095-006-9049-7.","journal-title":"Pharm Res"},{"key":"986_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00228-011-1023-6","volume":"67","author":"S Salman","year":"2011","unstructured":"Salman S, Sy SKB, Ilett KF, Page-Sharp M, Paech MJ. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. Eur J Clin Pharmacol. 2011;67:899\u2013908. https:\/\/doi.org\/10.1007\/s00228-011-1023-6.","journal-title":"Eur J Clin Pharmacol"},{"key":"986_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1365-2710.2004.00590.x","volume":"29","author":"SH Gan","year":"2004","unstructured":"Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Jelliffe RW. Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. J Clin Pharm Ther. 2004;29:455\u201363. https:\/\/doi.org\/10.1111\/j.1365-2710.2004.00590.x.","journal-title":"J Clin Pharm Ther"},{"key":"986_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13318-018-0491-9","volume":"44","author":"H Dooner","year":"2019","unstructured":"Dooner H, Mundin G, Mersmann S, Bennett C, Lorch U, Encabo M, et\u00a0al. Pharmacokinetics of tramadol and celecoxib in Japanese and Caucasian subjects following administration of co-crystal of tramadol-celecoxib (CTC): a randomised, open-label study. Eur J Drug Metab Pharmacokinet. 2019;44:63\u201375. https:\/\/doi.org\/10.1007\/s13318-018-0491-9.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"986_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/DDDT.S199574","volume":"13","author":"J Lee","year":"2019","unstructured":"Lee J, Yoo H-D, Bae J-W, Lee S, Shin K-H. Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6. Drug Des Dev Ther. 2019;13:1751\u201361. https:\/\/doi.org\/10.2147\/DDDT.S199574.","journal-title":"Drug Des Dev Ther"},{"key":"986_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s13318-022-00756-x","volume":"47","author":"AA Al-Qurain","year":"2022","unstructured":"Al-Qurain AA, Upton RN, Tadros R, Roberts MS, Wiese MD. Population pharmacokinetic model for tramadol and O-desmethyltramadol in older patients. Eur J Drug Metab Pharmacokinet. 2022;47:387\u2013402. https:\/\/doi.org\/10.1007\/s13318-022-00756-x.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"986_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2217\/pgs-2020-0026","volume":"21","author":"M Saiz-Rodr\u00edguez","year":"2020","unstructured":"Saiz-Rodr\u00edguez M, Ochoa D, Rom\u00e1n M, Zubiaur P, Koller D, Mej\u00eda G, et\u00a0al. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. Pharmacogenomics. 2020;21:663\u201375. https:\/\/doi.org\/10.2217\/pgs-2020-0026.","journal-title":"Pharmacogenomics"},{"key":"986_CR22","doi-asserted-by":"publisher","DOI":"10.2349\/biij.4.1.e5","volume":"4","author":"A Vijayananthan","year":"2008","unstructured":"Vijayananthan A, Nawawi O. The importance of good clinical practice guidelines and its role in clinical trials. Biomed Imaging Interv J. 2008;4:e5. https:\/\/doi.org\/10.2349\/biij.4.1.e5.","journal-title":"Biomed Imaging Interv J"},{"key":"986_CR23","unstructured":"World Medical Association World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Disponible En Internet. Consultado El 20-05-2020. 2013."},{"key":"986_CR24","unstructured":"National Institute of Health RefSeq: NCBI Reference Sequence Database."},{"key":"986_CR25","unstructured":"Dutch Pharmacogenetics Working Group Annotation of DPWG Guideline for Quetiapine and CYP3A4. 2021."},{"key":"986_CR26","unstructured":"Clinical Pharmacogenetics Implementation Consortium CPIC Website."},{"key":"986_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/bja\/aei170","volume":"95","author":"K Allegaert","year":"2005","unstructured":"Allegaert K, Anderson BJ, Verbesselt R, Debeer A, De Hoon J, Devlieger H, et\u00a0al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth. 2005;95:231\u20139. https:\/\/doi.org\/10.1093\/bja\/aei170.","journal-title":"Br J Anaesth"},{"key":"986_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2014.07.013","volume":"473","author":"N Brvar","year":"2014","unstructured":"Brvar N, Mateovi\u0107-Rojnik T, Grabnar I. Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations. Int J Pharm. 2014;473:170\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.07.013.","journal-title":"Int J Pharm"},{"key":"986_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711\u201326. https:\/\/doi.org\/10.1007\/s10928-007-9066-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"986_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1185\/030079906X162773","volume":"23","author":"BP Murthy","year":"2007","unstructured":"Murthy BP, Skee DM, Danyluk AP, Brett V, Vorsanger GJ, Moskovitz BL. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol. Curr Med Res Opin. 2007;23:275\u201384. https:\/\/doi.org\/10.1185\/030079906X162773.","journal-title":"Curr Med Res Opin"},{"key":"986_CR31","unstructured":"PsN Pearl Speaks NONMEM Documentation."},{"key":"986_CR32","unstructured":"PharmVar PharmVar. Pharmacogene Variation Consortium."},{"key":"986_CR33","volume-title":"Parameters for compartment-free pharmacokinetics: standardisation of study design, data analysis and reporting","author":"W Cawello","year":"1999","unstructured":"Cawello W, Brett M, Weimann H-J, Zimmerman H, Pabst G, Sierakowski B, et\u00a0al. Parameters for compartment-free pharmacokinetics: standardisation of study design, data analysis and reporting. Aachen: Shaker Verlag; 1999."},{"key":"986_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40263-019-00623-5","volume":"33","author":"A Barakat","year":"2019","unstructured":"Barakat A. Revisiting tramadol: a multi-modal agent for pain management. CNS Drugs. 2019;33:481\u2013501. https:\/\/doi.org\/10.1007\/s40263-019-00623-5.","journal-title":"CNS Drugs"},{"key":"986_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030331","volume":"18","author":"C Portol\u00e9s-D\u00edez","year":"2025","unstructured":"Portol\u00e9s-D\u00edez C, Salas-Butr\u00f3n MR, Ascaso-Del-Rio A, Rivas-Paterna AB, Laredo-Velasco L, Calandria C, et\u00a0al. Intravenous vs. oral dose comparison of ibuprofen and tramadol combinations-enantiomers, metabolite, linearity, and sex-related effects: a pharmacokinetics randomized clinical trial. Pharmaceuticals (Basel). 2025;18:331. https:\/\/doi.org\/10.3390\/ph18030331.","journal-title":"Pharmaceuticals (Basel)"},{"key":"986_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6623269","volume":"2023","author":"AM Bagher","year":"2023","unstructured":"Bagher AM. Association of CYP2C9\u22173 and CYP2C8\u22173 non-functional alleles with ibuprofen-induced upper gastrointestinal toxicity in a Saudi patient. Case Rep Med. 2023;2023:6623269. https:\/\/doi.org\/10.1155\/2023\/6623269.","journal-title":"Case Rep Med"},{"key":"986_CR37","unstructured":"Horde GW, Gupta V. Drug clearance. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing."},{"key":"986_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0976500X221107494","volume":"13","author":"HS Dasgupta","year":"2022","unstructured":"Dasgupta HS, Sahoo DP, Barman B, Brahma D. Low-dose tramadol-induced seizure: a case report. J Pharmacol Pharmacother. 2022;13:203\u20136. https:\/\/doi.org\/10.1177\/0976500X221107494.","journal-title":"J Pharmacol Pharmacother"},{"key":"986_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115281","volume":"166","author":"J Gouju","year":"2023","unstructured":"Gouju J, Legeay S. Pharmacokinetics of obese adults: not only an increase in weight. Biomed Pharmacother. 2023;166:115281. https:\/\/doi.org\/10.1016\/j.biopha.2023.115281.","journal-title":"Biomed Pharmacother"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00986-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-00986-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-00986-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:23:48Z","timestamp":1774625028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-00986-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["986"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-00986-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.A.-S. and D.O. have been consultants or investigators in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, Cinfa, FAES, Farmal\u00edder, Ferrer, GlaxoSmithKline, Galenicum, Gilead, Italfarmaco, Janssen-Cilag, Kern, Moderna, MSD, Normon, Novartis, Servier, Silver Pharma, Teva, and Zambon. The remaining authors declare no conflicts of interest. Georg Hempel is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      . Georg Hempel was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data proceeded from a bioequivalence clinical trial conducted at the Clinical Trials Unit of the Hospital Universitario de La Princesa (UECHUP), Madrid, Spain (EUDRA\u2010CT: 2013\u2010000196\u201032). The protocol and the informed consent form of the clinical trial and the pharmacogenetic study (code SFC-FG-2020-1, IRB\/Code: 4176) were revised and approved by the Spanish Drug Agency (AEMPS) and the Ethics Committee on Clinical Research with Drugs of the Hospital Universitario de La Princesa. The clinical trial and the posterior research were performed complying with the Good Clinical Practice guidelines, the Declaration of Helsinki, and the current Spanish legislation regarding clinical trials [\n                      \n                      ,\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all subjects involved in the clinical trials and in the observational study. Since no identifying details were included, no additional specific consent for publication was needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}}]}}